COVID-19 vaccination is not associated with heart transplant-specific adverse events
Moderna Asks FDA to Authorize Its COVID-19 Vaccine for Children Under 6
Preliminary analysis indicates vaccine efficacy of 51 percent among children younger than 2 years and 37 percent among children 2 to 5 years
SARS-CoV-2 Seroprevalence Up From Dec. 2021 to Feb. 2022
By February 2022, seroprevalence reached 75.2 percent among children aged 0 to 11 years, 74.2 percent for teens aged 12 to 17 years
Food Insecurity Tied to Delayed, Forgone Medical Care
Food insecurity during the pandemic disproportionately affected non-White and low-income individuals
Natural COVID-19 Immunity Produces Protection Similar to Vaccines
Similar natural protection seen against mild and severe disease
Myocarditis, Pericarditis Risk Highest After Second COVID-19 Vaccine Dose
In large cohort, there were 5.55 excess events per 100,000 vaccinees after BNT162b2 and 18.39 after mRNA-1273
Pfizer Seeks FDA Approval of COVID-19 Boosters for Children Ages 5 to 11
Initial two-dose series of the Pfizer vaccine was authorized for that age group in October
FDA Approves First COVID-19 Treatment for Use in Children
Veklury had already been fully approved to treat people 12 years and older
Risk for Guillain-Barré Syndrome Up After Ad.26.COV2.S Vaccination
Adjusted rate ratio of 20.56 found in head-to-head comparison of Ad.26.COV2.S with mRNA COVID-19 vaccines